These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
601 related articles for article (PubMed ID: 34428337)
1. Comparison of standard versus low-dose valganciclovir regimens for cytomegalovirus prophylaxis in high-risk liver transplant recipients. Bixby AL; Fitzgerald L; Park JM; Kaul D; Tischer S Transpl Infect Dis; 2021 Oct; 23(5):e13713. PubMed ID: 34428337 [TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of low-dose valganciclovir in the prevention of cytomegalovirus disease in adult liver transplant recipients. Park JM; Lake KD; Arenas JD; Fontana RJ Liver Transpl; 2006 Jan; 12(1):112-6. PubMed ID: 16382458 [TBL] [Abstract][Full Text] [Related]
3. Low-dose valganciclovir for cytomegalovirus prophylaxis in intermediate-risk liver transplantation recipients. Khan S; Sullivan T; Ali M; Dunn D; Patel G; Huprikar S Liver Transpl; 2018 May; 24(5):616-622. PubMed ID: 29500912 [TBL] [Abstract][Full Text] [Related]
4. Multicenter evaluation of efficacy and safety of low-dose versus high-dose valganciclovir for prevention of cytomegalovirus disease in donor and recipient positive (D+/R+) renal transplant recipients. Heldenbrand S; Li C; Cross RP; DePiero KA; Dick TB; Ferguson K; Kim M; Newkirk E; Park JM; Sudaria-Kerr J; Tichy EM; Ueda KR; Weng R; Wisniewski J; Gabardi S Transpl Infect Dis; 2016 Dec; 18(6):904-912. PubMed ID: 27639246 [TBL] [Abstract][Full Text] [Related]
5. Incidence of valganciclovir-related leukopenia and neutropenia in solid organ transplant recipients at high risk of cytomegalovirus disease. Belga S; Hernandez C; Kabbani D; Cervera C Transpl Infect Dis; 2024 Apr; 26(2):e14227. PubMed ID: 38180285 [TBL] [Abstract][Full Text] [Related]
7. Valganciclovir (VGCV) followed by cytomegalovirus (CMV) hyperimmune globulin compared to VGCV for 200 days in abdominal organ transplant recipients at high risk for CMV infection: A prospective, randomized pilot study. Fleming JN; Taber DJ; Weimert NA; Nadig S; McGillicuddy JW; Bratton CF; Baliga PK; Chavin KD Transpl Infect Dis; 2017 Dec; 19(6):. PubMed ID: 28921781 [TBL] [Abstract][Full Text] [Related]
8. Evaluation of Low- Versus High-dose Valganciclovir for Prevention of Cytomegalovirus Disease in High-risk Renal Transplant Recipients. Gabardi S; Asipenko N; Fleming J; Lor K; McDevitt-Potter L; Mohammed A; Rogers C; Tichy EM; Weng R; Lee RA Transplantation; 2015 Jul; 99(7):1499-505. PubMed ID: 25643140 [TBL] [Abstract][Full Text] [Related]
9. Valganciclovir is an effective prophylaxis for cytomegalovirus disease in liver transplant recipients. Fayek SA; Mantipisitkul W; Rasetto F; Munivenkatappa R; Barth RN; Philosophe B HPB (Oxford); 2010 Dec; 12(10):657-63. PubMed ID: 21083790 [TBL] [Abstract][Full Text] [Related]
10. Extended Low-Dose Valganciclovir Is Effective Prophylaxis Against Cytomegalovirus in High-Risk Kidney Transplant Recipients With Near-Complete Eradication of Late-Onset Disease. Fayek SA; Beshears E; Lieber R; Alvey N; Sauer A; Poirier J; Hollinger EF; Olaitan OK; Jensik S; Geyston J; Brokhof MM; Hodowanec AC; Hertl M; Simon DM Transplant Proc; 2016; 48(6):2056-2064.e1. PubMed ID: 27569944 [TBL] [Abstract][Full Text] [Related]
11. Low dose valganciclovir as cytomegalovirus prophylaxis in post-renal transplant recipients induced with alemtuzumab: A single-center study. Korneffel K; Mitro G; Buschor K; Rees M; Ortiz J Transpl Immunol; 2019 Oct; 56():101226. PubMed ID: 31344441 [TBL] [Abstract][Full Text] [Related]
12. Valganciclovir prophylaxis versus preemptive therapy in cytomegalovirus-positive renal allograft recipients: 1-year results of a randomized clinical trial. Witzke O; Hauser IA; Bartels M; Wolf G; Wolters H; Nitschke M; Transplantation; 2012 Jan; 93(1):61-8. PubMed ID: 22094954 [TBL] [Abstract][Full Text] [Related]
13. Low-dose valganciclovir prohylaxis is efficacious and safe in cytomegalovirus seropositive heart transplant recipients with anti-thymocyte globulin. Eriksson M; Jokinen JJ; Söderlund S; Hämmäinen P; Lommi J; Lemström K Transpl Infect Dis; 2018 Jun; 20(3):e12868. PubMed ID: 29512249 [TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of low-dose valganciclovir for prevention of cytomegalovirus disease in renal transplant recipients: a single-center, retrospective analysis. Gabardi S; Magee CC; Baroletti SA; Powelson JA; Cina JL; Chandraker AK Pharmacotherapy; 2004 Oct; 24(10):1323-30. PubMed ID: 15628830 [TBL] [Abstract][Full Text] [Related]
16. Oral Valganciclovir as a Preemptive Treatment for Cytomegalovirus (CMV) Infection in CMV-Seropositive Liver Transplant Recipients. Kim JM; Kwon CH; Joh JW; Ha YE; Sinn DH; Choi GS; Peck KR; Lee SK PLoS One; 2015; 10(5):e0123554. PubMed ID: 25942443 [TBL] [Abstract][Full Text] [Related]
17. Evaluating the efficacy and safety of letermovir compared to valganciclovir for the prevention of human cytomegalovirus disease in adult lung transplant recipients. Martinez S; Sindu D; Nailor MD; Cherrier L; Tokman S; Walia R; Goodlet KJ Transpl Infect Dis; 2024 Jun; 26(3):e14279. PubMed ID: 38742601 [TBL] [Abstract][Full Text] [Related]
18. Oral valganciclovir versus intravenous ganciclovir as preemptive treatment for cytomegalovirus infection after living donor liver transplantation: a randomized trial. Togashi J; Sugawara Y; Hashimoto M; Tamura S; Kaneko J; Aoki T; Hasegawa K; Kokudo N Biosci Trends; 2011; 5(5):217-22. PubMed ID: 22101378 [TBL] [Abstract][Full Text] [Related]
19. Oral ganciclovir versus valganciclovir for cytomegalovirus prophylaxis in high-risk liver transplant recipients. Brady RL; Green K; Frei C; Maxwell P Transpl Infect Dis; 2009 Apr; 11(2):106-11. PubMed ID: 19054381 [TBL] [Abstract][Full Text] [Related]
20. Does valganciclovir hydrochloride (valcyte) provide effective prophylaxis against cytomegalovirus infection in liver transplant recipients? Jain A; Orloff M; Kashyap R; Lansing K; Betts R; Mohanka R; Menegus M; Ryan C; Bozorgzadeh A Transplant Proc; 2005 Sep; 37(7):3182-6. PubMed ID: 16213344 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]